×
About 755 results

ALLMedicine™ Papillary Renal Cell Carcinoma Center

Research & Reviews  285 results

Savolitinib vs. Sunitinib in MET-driven PRCC.
https://clinicaltrials.gov/ct2/show/NCT03091192

May 20th, 2022 - This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is ef...

Papillary Renal Cell Carcinoma With "Drop Metastasis" (Tumor Seeding) Involving the Dis...
https://doi.org/10.1016/j.mayocp.2022.03.013
Mayo Clinic Proceedings; Gupta S, Erickson LA

May 6th, 2022 - Papillary Renal Cell Carcinoma With "Drop Metastasis" (Tumor Seeding) Involving the Distal Ureter.|2022|Gupta S,Erickson LA,|pathology,pathology,pathology,pathology,

Ten-year follow-up of renal adenomatosis with magnetic resonance imaging: a case report.
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9026678
Journal of Medical Case Reports; Chou YC, Lee WY et. al.

Apr 23rd, 2022 - Renal adenomatosis is a rare disease that presents as multiple papillary adenomas in the bilateral kidneys. Moreover, papillary adenoma is considered a precursor to papillary renal cell carcinoma. Therefore, patients with renal adenomatosis may ha...

Prognostic Significance of C-reactive Protein in Patients With Non-metastatic Papillary...
https://doi.org/10.1016/j.clgc.2022.03.004
Clinical Genitourinary Cancer; Toide M, Saito K et. al.

Apr 13th, 2022 - C-reactive protein is a useful biomarker for screening renal cell carcinoma (RCC); however, its significance in papillary RCC is unclear. We assessed the prognostic effect of serum C-reactive protein levels in patients with surgically treated non-...

see more →

Clinicaltrials.gov  7 results

Savolitinib vs. Sunitinib in MET-driven PRCC.
https://clinicaltrials.gov/ct2/show/NCT03091192

May 20th, 2022 - This study is designed for patients diagnosed with MET-driven, unresectable and locally advanced or metastatic Papillary Renal Cell Carcinoma. The purpose of this study is to see if an investigational new anti-cancer medication, savolitinib, is ef...

Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
https://clinicaltrials.gov/ct2/show/NCT05287945

Mar 18th, 2022 - This is an open, non-controlled, phase I/II study evaluating the safety, tolerability, and anti-tumor efficacy of orellanine treatment in patients with metastatic clear-cell or papillary renal carcinoma. The study will include up to 40 patients. T...

A Phase 2 Study of the MET Kinase Inhibitor INC280 in Papillary Renal Cell Cancer
https://clinicaltrials.gov/ct2/show/NCT02019693

Dec 21st, 2021 - Background: Papillary RCC is the second most common histologic subtype of kidney cancer, accounting for approximately 10-15% of cases Type 1 papillary RCC occurs in both sporadic and hereditary forms, which are histologically identical. Non famili...

A Phase II Trial to Evaluate the Efficacy of AZD6094 (HMPL-504) in Patients With Papillary Renal Cell Carcinoma (PRCC)
https://clinicaltrials.gov/ct2/show/NCT02127710

Apr 19th, 2021 - The study will comprise two stages. In Stage 1 approximately 20 patients will be enrolled. This group is considered sufficient to provide preliminary assessment of the anti-tumour activity of AZD6094 in the form of non-binding futility analysis. I...

Sunitinib as First-Line Therapy in Treating Patients With Locally Advanced Metastatic Papillary Renal Cell Cancer
https://clinicaltrials.gov/ct2/show/NCT00541008

Feb 21st, 2021 - OBJECTIVES: Primary To determine the objective tumor response rate in patients with locally advanced or metastatic papillary renal cell carcinoma treated with sunitinib malate. Secondary To evaluate the safety of this drug in these patients. To de...

see more →

News  10 results

Frontline mRCC Paradigm Crowds Among Immune-Based Treatment Options
https://www.onclive.com/view/frontline-mrcc-paradigm-crowds-among-immune-based-treatment-options

Mar 13th, 2021 - The emergence of multiple combination regimens with immunotherapy and tyrosine kinase inhibitors (TKIs) has been welcome for the frontline treatment of patients with metastatic renal cell carcinoma (mRCC); however, without head-to-head comparative...

Cabozantinib Could Be New Standard for Papillary RCC
https://www.medscape.com/viewarticle/945955

Feb 17th, 2021 - When treating metastatic papillary renal cell carcinoma (RCC), cabozantinib outperforms the current standard of care, according to results from the Southwest Oncology Group (SWOG) 1500 trial. Compared with the VEGFR-2 inhibitor sunitinib, the MET ...

Cabozantinib could be new standard for papillary RCC
https://www.mdedge.com/hematology-oncology/article/235981/genitourinary-cancer/cabozantinib-could-be-new-standard-papillary
Susan London

Feb 16th, 2021 - When treating metastatic papillary renal cell carcinoma (RCC), cabozantinib outperforms the current standard of care, according to results from the Southwest Oncology Group (SWOG) 1500 trial. Dr.

When to Consider Referral to a Genetic Counselor for Lesser Known Cancer Syndromes
https://www.onclive.com/view/when-to-consider-referral-to-a-genetic-counselor-for-lesser-known-cancer-syndromes

Dec 5th, 2020 - Abstract This article reviews two newly described cancer syndromes: DICER1 and BAP1 tumor predisposition syndrome, and four uncommon syndromes: Familial Atypical Multiple Mole Melanoma (FAMMM) syndrome, Hereditary Leiomyomatosis and Renal Cell Ca...

Savolitinib Might Improve Outcomes in Some Patients With Papillary Renal Cell Carcinoma
https://www.medscape.com/viewarticle/931729

Jun 8th, 2020 - NEW YORK (Reuters Health) - Savolitinib appears to improve outcomes in patients with MET-driven papillary renal-cell carcinoma (PRCC) compared with sunitinib, the standard of care, according to results from the SAVOIR randomized clinical trial. Th...

see more →